Skip to main content

Table 7 Selectivity ratio of MAKV-8-imatinib co-treatment for cancer cells versus healthy models

From: Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells

CML cells

Selectivity ratio

PBMCs

RPMI-1788

K-562

5.8

3.9

KBM-5

8.5

9.2

MEG-01

2.2

1.5

  1. Values were calculated from the percentage of cancer cell death versus healthy cell death from three independent experiments
  2. PBMCs peripheral blood mononuclear cells
Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us